<DOC>
	<DOCNO>NCT01083563</DOCNO>
	<brief_summary>The purpose study examine effect anti-TNF therapy rheumatoid arthritis use magnetic resonance imaging ( MRI ) ultrasound image . Anti-TNF therapy include group medication Enbrel , Remicade Humira affect body 's inflammatory response . These medication routinely prescribe treatment rheumatoid arthritis .</brief_summary>
	<brief_title>Draining PLN Synovial Inflammation RA Knee Joints Pre Post Anti-TNF B Cell Depletion Therapy</brief_title>
	<detailed_description>The specific aim study examine morphologic functional relationship drain PLN synovial inflammation knee joint RA patient therapy TNF antagonist B cell depletion therapy . The extensive search informative practical clinical biomarkers RA produce several candidate include CRP , anti-CCP antibody matrix metalloproteinase-3 ( MMP-3 ) , none soluble molecule predict disease progression high degree certainty , biomarker identify predict flare . Thus , finding PLN collapse precedes arthritis flare murine model offer novel biomarker may great value RA , require validation human . To end , propose two clinical pilot design test validity feasibility PLN assessment quantification active RA 3T CE-MRI Doppler US . The second goal pilot see relationship clinical response either TNF antagonist B cell depletion change size CE pattern PLN . The pilot study outline design test hypothesis effective clinical response anti-TNF BCDT associate increase drain LN function . While overall goal determine Doppler US predict flare , must first establish validity feasibility approach design clinical trial properly design adequately power . Aim A : To assess effect TNF inhibition volume CE PLN RA patient MRI , compare effectiveness Doppler US achieve outcome measure . Hypothesis : Rheumatoid synovitis knee trigger TNF over-expression monocytes/macrophages synovium and/or drain PLN , produce inflammation exceeds PLN drain capacity . This result decrease inflammatory cell egress joint arthritic flare . Effective anti-TNF therapy RA result increase PLN function due decrease cellularity lymphatic flow synovium drain node . Rationale : To address first hypothesis , plan determine validity feasibility drain LN function analyze ability 3T CE-MRI Doppler US quantify PLN inflamed RA knee . While CE-MRI ( volume x CE ) primary outcome measure PLN function base pre-clinical study , approach adaptable standard clinical practice . Furthermore , serial MRIs monitor flare RA feasible due cost , time , convenience availability resource . Thus , parallel US study perform determine instrument , gain acceptance rheumatology practice , generate accurate quantifiable PLN measurement . Aim B . To assess effect anti-CD20 therapy volume CE PLN RA patient `` flare '' period effective anti-TNF therapy . Hypothesis : RA flare patient effectively manage anti-TNF therapy cause local insult trigger B-cell migration precipitate LN shutdown decrease inflammatory cell egress joint . Effective anti-CD20 BCDT therapy patient correlate increase PLN function decrease inflammation synovium . Rationale : RA complex syndrome excess TNF production central disease pathogenesis . While ~70 % patient effectively manage anti-TNF therapy , additional insult ( i.e . local immune response trauma ) result flare adequately suppressed standard anti-TNF therapy patient ( 80 , 81 ) . Many patient flare one anti-TNF therapy respond BCDT ( 26 ) . An explanation fit preliminary finding TNF-Tg mouse local immune-inflammatory response share lymphatics RA synovium induce CXCL13 expression monocyte/macrophages drain LN cell soluble CXCL13 enter LN via lymphatics trigger mass migration B-cells paracortical sinus . This B cell translocation result decrease egress inflammatory cell , maintain anti-TNF therapy , manifest arthritic flare . To provide human correlate murine experiment design test hypothesis outline Aim 2 , produce feasibility data clinical trial test novel mechanism action , evaluate PLN radiographic change follow anti-CD20 BCDT RA patient flare anti-TNF therapy . We also assess DAS28 clinical response .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Inclusion Criteria Signed , IRBapproved , write informed consent Subjects either gender must 18 year old . Subjects must fulfill disease activity criterion RA DAS28 assess baseline 2 month rituximab therapy . Aim A Eligible subject must meet criterion RA inadequate response MTX define DAS28 &gt; 5.1 . They must steady dose MTX ( 15 20 mg /week minimum 8 week ) . Subjects must evidence knee synovitis exam enter study . Aim B Subjects must demonstrate response TNF antagonist evidence DAS score &lt; 2.8 &lt; 4 tender swollen joint . Flare define DAS 28 &gt; 5.1 8 swollen tender joint . Subjects must evidence knee synovitis enter study . Subjects etanercept , infliximab adalimumab 4 week start BCDT . All subject must also stable dose DMARD ( MTX , leflunomide , azulfidine , hydroxychloroquine ) 8 week entry study . Exclusion Criteria Patients exclude medical reason discretion investigator . The reason exclusion must record , e.g . risk noncompliance , vulnerability , medically unstable , etc . Active systemic disorder inflammatory condition ( i.e. , chronic infection hepatitis B , hepatitis C HIV ) condition study . Patients plasma creatinine &gt; 1.5 mg/dl Aim B Subjects allergy corticosteroid exclude study . Anyone answer yes follow question exclude : Do history : 1 . Cardiac ( Heart ) pacemaker defibrillator ? 2 . Cardiac ( Heart ) valve replacement prosthesis ? 3 . Aneurysm clip brain surgery ? 4 . Ear prosthesis ( cochlear stapedial implant ) ? ( hear aid ? ) 5 . Neurostimulator ? 6 . Biostimulator ? 7 . Any type pump body ? 8 . Shrapnel , gunshot wound , BB pellet ? 9 . Metallic penile prosthesis ? 10 . Metallic blood vessel filter stent ? 11 . Orthopedic prosthesis ? 12 . Have ever injury involve metal fragment eye ? 13 . Have ever neurosurgery ( brain skull surgery ) ? Note : Subjects treat rituximab exclude study base immunosuppressive drug use agent record discussed analysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>TNF</keyword>
	<keyword>CD20</keyword>
	<keyword>RA</keyword>
</DOC>